You have 9 free searches left this month | for more free features.

RMS

Showing 1 - 25 of 544

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

PET/MR for Characterization of Renal Masses (RMs)

Recruiting
  • Renal Tumor
  • +2 more
  • 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Oct 5, 2023

Multiple Sclerosis Trial (Dimethyl fumarate)

Not yet recruiting
  • Multiple Sclerosis
  • Dimethyl fumarate
  • (no location specified)
Dec 12, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021

Benign Paroxysmal Positional Vertigo Trial in Istanbul (Automated vertigo repositioning chair, Canalith Reposition Maneuver)

Completed
  • Benign Paroxysmal Positional Vertigo
  • Automated vertigo repositioning chair
  • Canalith Reposition Maneuver
  • Istanbul, Sultangazi, Turkey
    Haseki Sultangazi Training and Research Hospital
Apr 23, 2022

FFPE Samples From Younger Patients With Rhabdomyosarcoma

Completed
  • Alveolar Childhood Rhabdomyosarcoma
  • +2 more
    • Jinan, Shandong, China
      Jinan central hospital affiliated to Shandong First Medical Univ
    Sep 10, 2023

    Rhabdomyosarcoma, Child Trial (Realgar-Indigo Naturalis Formulation, Radiotherapy)

    Not yet recruiting
    • Rhabdomyosarcoma, Child
    • Realgar-Indigo Naturalis Formulation
    • Radiotherapy
    • (no location specified)
    Jan 31, 2023

    Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Ublituximab
    • Pasadena, California
    • +7 more
    Aug 19, 2022

    Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)

    Recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Fingolimod 0.5mg
    • Beijing, Beijing, China
    • +12 more
    Feb 3, 2022

    RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ofatumumab
    • Ocrelizumab
    • Dubai, United Arab Emirates
      Novartis Investigative Site
    Aug 8, 2022

    Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)

    Completed
    • Multiple Sclerosis
    • Blood draw for future biomarker analysis
    • Los Angeles, California
      Investigational Site Number 8400001
    Mar 15, 2022

    Multiple Sclerosis Trial in Germany (Ofatumumab)

    Active, not recruiting
    • Multiple Sclerosis
    • Berlin, Germany
    • +5 more
    Jan 13, 2023

    Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)

    Terminated
    • Multiple Sclerosis
    • Temelimab 18 mg/kg
    • +2 more
    • Stockholm, Sweden
      Center for Neurology, Academic Specialist Center
    Jul 4, 2022

    Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

    Completed
    • Relapsing Multiple Sclerosis (RMS)
    • Rebif (Interferon beta-1a)
    • Alger, Algeria
    • +40 more
    Mar 22, 2022

    Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

    Terminated
    • Relapsing-remitting Multiple Sclerosis
    • Rockland, Massachusetts
    • +1 more
    Jul 13, 2021

    Relapsing Multiple Sclerosis (RMS) Trial in Germany, Poland (Cladribine, Placebo, Microgynon®)

    Active, not recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Bochum, Germany
    • +6 more
    Feb 8, 2022

    Postoperative Complications, Surgery Trial (Intraoperative ventilation with individualized high PEEP titrated to the lowest ?P

    Not yet recruiting
    • Postoperative Complications
    • Surgery
    • Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs
    • (no location specified)
    Oct 24, 2023

    Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)

    Completed
    • Multiple Sclerosis
    • temelimab 18 mg/kg
    • +3 more
    • Stockholm, Sweden
      Center for Neurology, Academic Specialist Center
    Jul 4, 2022

    Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)

    Recruiting
    • Relapsing Forms of Multiple Sclerosis
    • EHP-101 25 mg OD
    • +3 more
    • Cullman, Alabama
    • +3 more
    Apr 29, 2022

    Coronary Artery Disease Trial in Switzerland (Magmaris Resorbable Magnesium Scaffold (RMS))

    Terminated
    • Coronary Artery Disease
    • Magmaris Resorbable Magnesium Scaffold (RMS)
    • Genève, Switzerland
    • +5 more
    Jul 29, 2022

    Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)

    Recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Phoenix, Arizona
    • +3 more
    Jul 20, 2022

    Relapsing Multiple Sclerosis Trial in Worldwide (Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Beijin, China
      Peking University Third Hospital
    Jul 6, 2021

    Complementary Feeding Trial in Ikeja, Kaduna (A&T IYCF intervention)

    Completed
    • Complementary Feeding
    • A&T IYCF intervention
    • Ikeja, Lagos, Nigeria
    • +1 more
    Jan 13, 2021

    Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia Trial (DREAMS 3G RMS, Xience DES)

    Not yet recruiting
    • Coronary Artery Disease
    • +5 more
    • DREAMS 3G RMS
    • Xience DES
    • (no location specified)
    Sep 12, 2022